Physician profile
Edison Tan
NPI 1962475533
$8,066.47
in general payments reported to CMS, 2019-2025
50 companies · $1,305 in 2025
The $1,305 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,085 · 2020: $771 · 2021: $1,201 · 2022: $1,046 · 2023: $1,631 · 2024: $1,028 · 2025: $1,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,963.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,262.62 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $1,161.65 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $748.59 | 2019-2022 | |
| Lilly USA, LLC | $725.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $675.07 | 2019-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $394.68 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $376.94 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $235.56 | 2019-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.40 | 2020-2025 | Jardiance |
| Glaxosmithkline, LLC. | $203.61 | 2019-2025 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $200.20 | 2019-2023 | |
| Pfizer INC. | $195.76 | 2020-2025 | |
| Antares Pharma, INC. | $188.78 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Amarin Pharma, INC. | $153.74 | 2020-2022 | |
| Dexcom, INC. | $138.97 | 2021-2025 | Dexcom G6 Transmitter |
Show all 47 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edison Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.